Massachusetts Financial Services
MRSN

Massachusetts Financial Services’s Mersana Therapeutics MRSN Stock Holding History

Massachusetts Financial Services’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,189
Closed -$791K – 951
2020
Q4 		$791K Sell
1,189
-2,006
-63% -$1.12M ﹤0.01% 813
2020
Q3 		$1.49M Buy
+3,195
New +$1.61M ﹤0.01% 749

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Massachusetts Financial Services's MRSN Position: Q1 2021 in Review

Massachusetts Financial Services sold out of Mersana Therapeutics (MRSN) in Q1 2021, closing a stake of 1,189 shares — an estimated $791K sold.

Massachusetts Financial Services first reported a position in MRSN in Q3 2020 and held it in 2 quarters. The position peaked at $1.49M in Q3 2020. 132 funds tracked by Wall St. Rank hold MRSN as of Q1 2021.

  • Massachusetts Financial Services reported no remaining Mersana Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Massachusetts Financial Services sold 1,189 Mersana Therapeutics shares in Q1 2021, an estimated $791K.
  • Massachusetts Financial Services first reported a position in Mersana Therapeutics in Q3 2020 and held it in 2 quarters.
  • Massachusetts Financial Services's Mersana Therapeutics position peaked at $1.49M in Q3 2020.
  • 132 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2021.

Based on Massachusetts Financial Services's 13F filing for Q1 2021, filed 13 May 2021.